Enhanced EMT Characteristics Associated with Unfavorable Tumor Microenvironment, Angiogenesis, and Poorer Prognosis in Gastric Cancer Academic Background Epithelial-Mesenchymal Transition (EMT) is an extremely important mechanism that promotes the metastasis of cancer cells. However, despite its apparent importance, the clinical significance of EMT...

LOXL1-AS1 Promotes Cholangiocarcinoma Progression by Regulating the JAK2/STAT3 Signaling Pathway Academic Background Cholangiocarcinoma (CCA) is a malignant tumor originating from biliary epithelium, presenting significant medical challenges. Its incidence shows geographical variation, being particularly high in Asia and South America. The occurren...

Single-Cell Atlas Reveals Immunosuppressive Microenvironment and Treg Cell Distribution in Recurrent Glioblastoma Glioblastoma is the most aggressive brain tumor, with a very high recurrence rate and poor prognosis. Although many studies have explored the tumor microenvironment of this disease, the understanding of the immune microenvironment in re...

Romidepsin Exhibits Anti-Esophageal Squamous Cell Carcinoma Activity through DDIT4-mTORC1 Pathway Esophageal squamous cell carcinoma (ESCC) is one of the most common human malignancies globally, with high incidence and mortality rates. Given the limited current treatment options, there is an urgent need to develop new effective therapeutic drugs. I...

Identification of Lineage-Specific Epigenetic Regulators FOXA1 and GRHL2 through Chromatin Accessibility Analysis of Breast Cancer Cell Lines Background Breast cancer is a highly heterogeneous disease currently classified clinically based on gene expression patterns, intrinsic molecular subtypes, and the expression of hormone receptors/human epider...

AAV-Mediated Trastuzumab Delivery to the Central Nervous System for EGFR2-Positive Brain Metastases Introduction In the treatment of breast cancer, tumors that are human epidermal growth factor receptor 2 (HER2) positive exhibit more aggressive characteristics, posing significant challenges for clinical treatment. Since the approval of trastuzumab ...